To summarise the role of MPS cells in the TME, evidence is mounting that immunomodulatory molecules such as PD-L1 and IDO-1, particularly on macrophages and, to a lesser degree, on other myeloid cells, are associated with poor prognosis in cHL. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.